Opioid-related overdose deaths represent a significant public health issue worldwide. In the UK, the majority of drug-related deaths are the result of poly-substance use, and commonly feature opioid drugs like heroin, morphine and methadone, consumed alongside other central nervous system depressants like benzodiazepines and alcohol.
Prenoxad Injection (naloxone hydrochloride 1mg/1ml solution for injection) contains 2 ml naloxone hydrochloride 1 mg/ml. Naloxone is a competitive opioid antagonist which can rapidly reverse the respiratory depression induced by heroin and other opioids. Naloxone competes for space at opioid receptors. It will temporarily remove opioids from the receptors and prevent opioids from re-attaching to the receptors for a limited period of time. Therefore, it may be used as an antagonist drug to reverse opioid and opioid-related overdose.
Following overdose by heroin injection, death occurs within 1 to 3 hours, limiting the window of opportunity to intervene. Furthermore, most drug overdose deaths occur in the company of others, with up to three-quarters of overdoses being witnessed by others.[1,4] Naloxone is well established in reversing opioid or opioid-related overdoses in the context of routine post-operative use in the hospital setting as well as in emergency settings for users of illegal opiates, when administered by physicians, ambulance crews and trained healthcare professionals.
In 2005, a change in the UK Medicines Act allowed naloxone to be administered by anyone for the purpose of saving life in an emergency.
Prenoxad Injection is the first presentation of naloxone to be licensed for emergency use in the home or other non-medical setting by appropriate individuals for the complete or partial reversal of respiratory depression induced by opioids. It should be carried by persons at risk of opioid overdose.
Prenoxad Injection remains a prescription only medicine and can be supplied to a person at risk of opioid overdose, but it can also be given by anyone present at the scene of an overdose that is in a position to intervene in advance of the emergency services attending. It can also be supplied to the friends, family or other representative of someone identified at risk of opioid or opioid-related overdose, but only with the written consent from the person for whom it is to be supplied. Prenoxad Injection can only be made available once the prescriber has assessed the suitability and competence of a client or representative to administer it in the appropriate circumstances.
On this website you will find further information on how prescribing and dispensing Prenoxad Injection, as well as how Prenoxad Injection should be used.
Presentation: A 2ml pre-filled syringe containing Naloxone Hydrochloride 1mg/ml.
Indications: Prenoxad Injection is intended for emergency use in the home or other non-medical setting by appropriate individuals or in a health facility setting for the complete or partial reversal of respiratory depression induced by natural and synthetic opioids, including methadone, diamorphine (dicetylemorphine (INN)) and certain other opioids such as dextropropoxyphene and certain mixed agonist/antagonist analgesics: nalbuphine and pentazocine. Prenoxad Injection should be carried by persons at risk of such events. It may also be used for the diagnosis of suspected acute opioid overdose.
Dosage and Administration: : Prenoxad Injection may only be made available once the prescriber has assessed the suitability and competence of a client or representative to administer Naloxone in the appropriate circumstances. Prenoxad Injection is for administration by intramuscular injection.
Adults and the Elderly: Opioid overdosage (known or suspected). For Use by individuals in the community.
In patients where breathing does not appear to be normal. In patients where breathing does not appear to be normal administration of Prenoxad Injection should be preceded by calling emergency services and requesting an ambulance. Following this, 30 chest compressions and if possible 2 rescue breaths (Basic Life Support SINGLE CYCLE) should be given; 0.4ml Prenoxad Injection solution should then be administered by intramuscular injection into the outer thigh muscle or muscles of the upper arm, through clothing if necessary. A further 3 cycles of chest compressions and rescue breaths should then be given followed by administration of 0.4ml Prenoxad Injection. Three cycles of chest compression and rescue breaths should take approximately 2 minutes. This should be repeated until an ambulance arrives or the patient begins breathing normally / regains consciousness. The patient when breathing normally or has regained consciousness should be placed in the recovery position (lying on their side, mouth open pointing towards the ground) and observed continuously.
In patients were breathing is normal but the patient is unrousable or suspected to be unconscious. The patient should be placed in the recovery position. 0.4ml Prenoxad Injection solution should be administered by intramuscular injection into the outer thigh muscle or muscles of the upper arm, through clothing if necessary, and an ambulance should be called. 0.4ml Prenoxad Injection solution should then be administered every 2-3 minutes and continued until the ambulance arrives and or the patient regains consciousness.
Children and Neonates: The Prenoxad Injection presentation is not intended to be used for children in the home setting other than by an appropriately trained healthcare professional.
Contra-Indications: Known hypersensitivity to Naloxone or any of the ingredients.
Warnings And Precautions: Prenoxad Injection is intended as an emergency treatment and the patient should be advised to seek medical help immediately.It should be administered cautiously to patients who have received large doses of opioids or to those physically dependent on opioids since too rapid reversal of opioid effects by Prenoxad may precipitate an acute withdrawal syndrome in such patients. Patients who have responded satisfactorily to Prenoxad should be kept under medical observation for at least 2 hours. Repeated doses of Prenoxad may be necessary since the duration of action of some opioids may exceed that of Prenoxad. Use with caution in patients with pre-existing cardiac, hepatic or renal disease and in those receiving medications with potential adverse cardiovascular effects e.g. hypotension, ventricular tachycardia or fibrillation and pulmonary oedema. Caution should be exercised and patients monitored when Prenoxad Injection is administered to this patients with renal insufficiency/failure or liver disease.
Interactions: Administer cautiously to opioid dependent patients including newborns of mother’s dependant or those suspected of having received large doses and observe for signs of acute withdrawal.
Pregnancy and Lactation:Prenoxad should be used with caution in pregnancy. The neonate must also be monitored for signs of opioid withdrawal. Naloxone may be administered during the second stage of labour to correct any respiratory depression due opioid analgesics. It is not known whether Naloxone is excreted in human milk therefore use with caution in breastfeeding mothers.
Undesirable Effects:Common side effects include nausea, vomiting, dizziness, headache, ventricular tachycardia, hypotension and hypertension. Less common side effects: Tremor, sweating, arrhythmia, bradycardia, diarrhoea, dry mouth, hyperventilation, inflammation. Seizure tension, allergic recations, anaphylactic shock, fibrillation, cardiac arrest, erythema multiforme, fever, dyspnoea, runny nose, sneezing and yawning. Piloerection, weakness, shivering.
Product Licence Number: PL 12064/0125 Product Licence Holder: Aurum Pharmaceuticals Ltd, Bampton Road, Harold Hill, Romford, Essex RM3 8UG Basic NHS Price: £18.00 Legal Category: POM. Date of Preparation: April 2013
For more details contact: Aurum Pharmaceuticals ubert Road, Brentwood, Essex CM14 4LZ 01277 266600
For the purposes of the Data Protection Act 1998, the data controller is Macarthys Laboratories Limited trading as “Martindale Pharma”.
This site may actively collect and process information from you by asking you specific questions; and by permitting you to communicate directly with us via e-mail, employment applications, surveys and/or feedback forms. Some of the information that you submit may be personally identifiable information (e.g., e-mail address). Please note that we may ask you for information when you report a problem with this site. Further, some areas of this site may require you to submit information in order for you to benefit from the specified features (e.g., newsletters, employment applications) or to participate in a particular activity (e.g., promotions). You will be informed in each instance what information is required, the purpose for which it is collected and what information is optional.
As you navigate through a web site, certain information can be passively collected using various technologies and means including Internet Protocol (IP) and Cookies.
This site may use IP addresses. An IP address is a number assigned to your computer by your Internet service provider so you can access the Internet. We use your IP address to analyse trends, track user’s movements, gather broad demographic information for aggregate use and administer and improve the site.
This site uses session cookies. “Session” cookies are temporary bits of information that are erased once you exit your web browser window or otherwise turn your computer off. Session cookies are used to improve navigation on web sites and to collect aggregate statistical information. For example, session cookies enable a website to remember that a user has placed items in an online shopping basket.
This site uses navigational data (“log files” and “server logs) for system management; to improve the content of this site; market research purposes; and to communicate information to visitors. You can change your browser settings so that cookies are not accepted. Please be aware that if you do this, you may lose some of the functionality of this site.
We use information held about you in the following ways:
We understand the importance of maintaining the confidentiality of your personal details, skills and interests and any other employment related information that you may supply when applying for a position with us or an affiliate.
If you are considered for employment by us your personal data may be shared with other companies acting on our behalf to provide employment verification services.
We will retain your personal data on file for up to six months and may contact you regarding future employment opportunities. You may withdraw from us holding your information at any time by advising us at email@example.com. You should be aware that providing false information may lead to rejection of the employment application or termination of any subsequent employment.
In addition, we will make full use of all information acquired through this site that is not in personally identifiable form.
You may contact us as indicated below to access, correct or update personally identifiable information about you. We will take reasonable steps to update or correct personally identifiable information in our possession that you have previously submitted via this site. We will keep your personally identifiable information for a reasonable period of time (bearing in mind the purpose for which your information was collected).
Whilst we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to this site; any transmission is at your own risk. We take reasonable steps to protect your personally identifiable information as you transmit your information from your computer to this site and to protect such information from loss, misuse, and unauthorised access, disclosure, alteration, or destruction. You should keep in mind that no Internet transmission is ever 100% secure or error-free. In particular, e-mail sent to or from this site may not be secure, and you should therefore take special care in deciding what information you send to us via e-mail. Moreover, where you use passwords, ID numbers, or other special access features on this site, it is your responsibility to safeguard them.
Our users are given the opportunity to ‘opt-out’ of having their information used for purposes not directly related to this site at the point where we ask for the information.
In the case of direct marketing, users will be asked for their consent (ie “opt-in”) before we process personally identifiable information for this purpose.
This site is not intended for children under the age of 13. We will not knowingly collect information from site visitors in this age group.
Tel: 01277 266600
For other queries visit our Contacts section